MCID: PST011
MIFTS: 50

Pustulosis of Palm and Sole

Categories: Skin diseases

Aliases & Classifications for Pustulosis of Palm and Sole

MalaCards integrated aliases for Pustulosis of Palm and Sole:

Name: Pustulosis of Palm and Sole 12 15
Psoriasis 45 74
Pustular Psoriasis of the Palms and/or Soles 12
Acrodermatitis Continua of Hallopeau 74
Generalized Pustular Psoriasis 74
Pustulosis of Palms and Soles 74
Palmoplantar Pustulosis 12
Acropustulosis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4398
MeSH 45 D011565
NCIt 51 C34888
SNOMED-CT 69 27520001
ICD10 34 L40.3

Summaries for Pustulosis of Palm and Sole

MalaCards based summary : Pustulosis of Palm and Sole, also known as psoriasis, is related to psoriatic arthritis and psoriasis 14, pustular, and has symptoms including pruritus, exanthema and psoriasiform rash. An important gene associated with Pustulosis of Palm and Sole is MRAP (Melanocortin 2 Receptor Accessory Protein), and among its related pathways/superpathways are Innate Lymphoid Cell Differentiation Pathways and Apoptosis and survival Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway. The drugs Apremilast and Angiogenesis Inhibitors have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and neutrophil.

Related Diseases for Pustulosis of Palm and Sole

Diseases related to Pustulosis of Palm and Sole via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 742)
# Related Disease Score Top Affiliating Genes
1 psoriatic arthritis 33.1 IL36RN TNF TNFRSF1B
2 psoriasis 14, pustular 32.5 AP1S3 IL36RN
3 pustulosis palmaris et plantaris 32.2 AP1S3 CCR6 IL36RN TNF
4 geographic tongue 32.0 IL36RN TNF
5 bone inflammation disease 30.5 MRAP TNF TNFRSF1B
6 pityriasis rubra pilaris 30.5 IL36RN TNFRSF1B
7 spondylitis 30.2 TNF TNFRSF1B
8 acrodermatitis 30.1 AP1S3 IL36RN
9 pustular psoriasis 30.0 AP1S3 IL36RN TNF
10 tenosynovitis 29.9 MRAP TNFRSF1B
11 spondyloarthropathy 1 29.9 MRAP TNF TNFRSF1B
12 subcorneal pustular dermatosis 29.8 IL36RN TNFRSF1B
13 pyoderma 29.8 IL36RN TNF
14 behcet syndrome 29.6 MRAP TNF TNFRSF1B
15 iritis 29.6 MRAP TNFRSF1B
16 orbital plasma cell granuloma 29.5 MRAP TNFRSF1B
17 posterior scleritis 29.2 MRAP TNF
18 guillain-barre syndrome 29.2 TNF TNFRSF1B
19 juvenile rheumatoid arthritis 29.1 TNF TNFRSF1B
20 periodic fever, familial, autosomal dominant 29.1 TNF TNFRSF1B
21 melkersson-rosenthal syndrome 28.9 TNF TNFRSF1B
22 exanthem 28.9 TNF TNFRSF1B
23 panuveitis 28.9 MRAP TNF TNFRSF1B
24 psoriasis 15, pustular 12.4
25 psoriasis 10 12.2
26 psoriasis 6 12.2
27 psoriasis 3 12.2
28 psoriasis 4 12.1
29 psoriasis 5 12.1
30 psoriasis 8 12.1
31 psoriasis 12 12.1
32 mental retardation and psoriasis 12.0
33 psoriasis 9 12.0
34 psoriatic juvenile idiopathic arthritis 12.0
35 tranebjaerg svejgaard syndrome 11.8
36 impetigo herpetiformis 11.7
37 parapsoriasis 11.4
38 chronic recurrent multifocal osteomyelitis 11.3
39 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 11.3
40 subacute cutaneous lupus erythematosus 11.3
41 psoriasis 1 11.3
42 singleton-merten syndrome 1 11.1
43 systemic onset juvenile idiopathic arthritis 11.1
44 nail disorder, nonsyndromic congenital, 1 11.0
45 singleton-merten syndrome 2 11.0
46 temporomandibular ankylosis 11.0
47 primary cutaneous amyloidosis 11.0
48 combined immunodeficiency with skin granulomas 11.0
49 singleton-merten syndrome 11.0
50 dermatitis 10.8

Graphical network of the top 20 diseases related to Pustulosis of Palm and Sole:



Diseases related to Pustulosis of Palm and Sole

Symptoms & Phenotypes for Pustulosis of Palm and Sole

UMLS symptoms related to Pustulosis of Palm and Sole:


pruritus, exanthema, psoriasiform rash

Drugs & Therapeutics for Pustulosis of Palm and Sole

Drugs for Pustulosis of Palm and Sole (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 27)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Apremilast Approved, Investigational Phase 4 608141-41-9 11561674
2 Angiogenesis Inhibitors Phase 4
3 Angiogenesis Modulating Agents Phase 4
4 Peripheral Nervous System Agents Phase 4,Phase 3
5 Anti-Bacterial Agents Phase 4
6 Anti-Inflammatory Agents Phase 4,Phase 3
7 Anti-Infective Agents Phase 4
8 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3
9 Immunosuppressive Agents Phase 4,Phase 3
10 Immunologic Factors Phase 4,Phase 3,Phase 2
11 Analgesics Phase 4,Phase 3
12 Antirheumatic Agents Phase 4,Phase 3,Phase 2
13 Analgesics, Non-Narcotic Phase 4,Phase 3
14 Antibodies Phase 4,Phase 3,Phase 2
15 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2
16 Immunoglobulins Phase 4,Phase 3,Phase 2
17
Etanercept Approved, Investigational Phase 3 185243-69-0
18
tannic acid Approved Phase 3 1401-55-4
19
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
20
Infliximab Approved Phase 3 170277-31-3
21
Ustekinumab Approved, Investigational Phase 3 815610-63-0
22 Gastrointestinal Agents Phase 3
23 Dermatologic Agents Phase 3,Phase 2
24
Alitretinoin Approved, Investigational Phase 2 5300-03-8 444795 449171
25 Antineoplastic Agents, Immunological Phase 2
26 Pharmaceutical Solutions Phase 2
27 Interleukin 1 Receptor Antagonist Protein Phase 2

Interventional clinical trials:

(show all 16)
# Name Status NCT ID Phase Drugs
1 Apremilast in Palmo-Plantar Psoriasis Completed NCT02400749 Phase 4 Apremilast;Placebo
2 Raptiva in Palm and Sole Psoriasis Terminated NCT00972543 Phase 4
3 A Placebo-Controlled Double-Blind Study on the Safety and Efficacy of Etanercept in Palmoplantar Pustulosis Completed NCT00353119 Phase 3 Placebo comparator;Etanercept
4 An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis Completed NCT02641730 Phase 3 Guselkumab;Placebo
5 Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab Completed NCT02008890 Phase 3
6 Safety and Efficacy of Infliximab in Palmoplantar Psoriasis Completed NCT00629772 Phase 3 Placebo;Infliximab
7 Safety and Efficacy of Ustekinumab in Patients With Palmo-Plantar Pustular Psoriasis or With Palmo-Plantar Pustulosis Terminated NCT01091051 Phase 3 Ustekinumab;Placebo (Soduim Chloride)
8 A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis Completed NCT01845987 Phase 2 Placebo;CNTO 1959
9 Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients Completed NCT03135548 Phase 2 BI 655130 (low dose);Placebo;BI 655130 (high dose)
10 Efficacy of Alitretinoin Treatment in Patients With Pustular Form of Psoriasis Completed NCT01245140 Phase 2 alitretinoin;Placebo
11 Study to Evaluate the Efficacy of Alefacept to Treat Palmar Plantar Pustulosis Completed NCT00301002 Phase 2 Alefacept
12 A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis Recruiting NCT03633396 Phase 2 Placebo
13 Anakinra for Inflammatory Pustular Skin Diseases Recruiting NCT01794117 Phase 2 Anakinra
14 Efficacy Study of TEPSO® Socks in Improving Palmoplantar Pustulosis Terminated NCT01197989 Phase 2
15 Immune Signature of Palmoplantar Pustulosis Completed NCT01780857
16 Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases Recruiting NCT01952275

Search NIH Clinical Center for Pustulosis of Palm and Sole

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: psoriasis

Genetic Tests for Pustulosis of Palm and Sole

Anatomical Context for Pustulosis of Palm and Sole

MalaCards organs/tissues related to Pustulosis of Palm and Sole:

42
Skin, T Cells, Neutrophil, Liver, Testes, Endothelial, Monocytes

Publications for Pustulosis of Palm and Sole

Articles related to Pustulosis of Palm and Sole:

(show top 50) (show all 2755)
# Title Authors Year
1
Apremilast as a new treatment option for Acrodermatitis continua of Hallopeau. ( 30623424 )
2019
2
Acrodermatitis continua of Hallopeau successfully treated with adalimumab: A case report. ( 30800311 )
2019
3
Acrodermatitis continua of Hallopeau response to optimized biological therapy. ( 30865417 )
2019
4
Distinguishing pustular psoriasis and acute generalized exanthematous pustulosis (AGEP) on the basis of plasmacytoid dendritic cells (PDCs) and MxA protein. ( 30667074 )
2019
5
Acute generalized exanthematous pustulosis (AGEP) and psoriasis: what can be learned from co-morbidities. A comparative study. ( 30762030 )
2019
6
Alexithymia and psoriasis: what is the link? ( 30714112 )
2019
7
Serum galectin-9 levels in atopic dermatitis, psoriasis and allergic contact dermatitis: A cross-sectional study. ( 30719989 )
2019
8
Patients with Moderate to Severe Psoriasis Associate with Higher Risk of Depression and Anxiety Symptoms: Results of a Multivariate Study of 300 Spanish Individuals with Psoriasis. ( 30628634 )
2019
9
A Chinese cross-sectional study on depression and anxiety symptoms in patients with psoriasis vulgaris. ( 30293440 )
2019
10
Unilateral Remission of Psoriasis Associated with a Spinal Arteriovenous Malformation. ( 30896775 )
2019
11
Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis. ( 30916734 )
2019
12
Serum lipid metabolism in psoriasis and psoriatic arthritis - an update. ( 30899289 )
2019
13
Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University Psoriasis Registry. ( 30861182 )
2019
14
Quality of life and contact with healthcare systems among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP). ( 30868221 )
2019
15
Ultrasonographic and Clinical Assessment of Peripheral Enthesitis in Patients with Psoriatic Arthritis, Psoriasis, and Fibromyalgia Syndrome: The ULISSE Study. ( 30877205 )
2019
16
The Potential Benefits of Certolizumab Pegol in Patients with Concurrent Psoriatic Arthritis and Chronic Plaque Psoriasis: A Case Series and Review of the Literature. ( 30879179 )
2019
17
A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation. ( 30885757 )
2019
18
Twenty Years Without Treatment: A Presentation of Arthritis Mutilans With Psoriasis. ( 30841733 )
2019
19
Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trials. ( 30792887 )
2019
20
Inflammatory dietary pattern and incident psoriasis, psoriatic arthritis, and atopic dermatitis in women: a cohort study. ( 30797850 )
2019
21
Use of secukinumab in a pediatric patient leads to significant improvement in nail psoriasis and psoriatic arthritis. ( 30811618 )
2019
22
Relapse of psoriatic arthritis in patients with active psoriasis swapped from TNF-α to IL-17A inhibitor. ( 30820927 )
2019
23
Analyses of association of psoriatic arthritis and psoriasis vulgaris with functional NCF1 variants. ( 30753645 )
2019
24
Subclinical synovitis and enthesitis in psoriasis patients and controls by ultrasonography in Saudi Arabia; incidence of psoriatic arthritis during two years. ( 30756253 )
2019
25
Efficacy of secukinumab in psoriasis and psoriatic arthritis: A retrospective multicentre study. ( 30717997 )
2019
26
Evaluation of subclinical gut inflammation using fecal calprotectin levels and colonic mucosal biopsy in psoriasis and psoriatic arthritis patients. ( 30729502 )
2019
27
Does weight loss reduce the severity and incidence of psoriasis or psoriatic arthritis? A critically-appraised topic. ( 30729517 )
2019
28
An interleukin-17 inhibitor successfully treated a complicated psoriasis and psoriatic arthritis patient with hepatitis B virus infection and end-stage kidney disease on hemodialysis. ( 30733983 )
2019
29
Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs. ( 30739254 )
2019
30
Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. ( 30742092 )
2019
31
Plasma TNF-α and adiponectin levels differentiate psoriatic arthritis from psoriasis patients. ( 30695115 )
2019
32
Safety and Efficacy of Methotrexate for Chinese Adults With Psoriasis With and Without Psoriatic Arthritis. ( 30698628 )
2019
33
Polymorphisms associated with anti-TNF drugs response in patients with psoriasis and psoriatic arthritis. ( 30653751 )
2019
34
Spanish Validation of the GEPARD Questionnaire for the Detection of Psoriatic Arthritis in Argentinian Patients with Psoriasis. ( 30654384 )
2019
35
Utilization of the validated Psoriasis Epidemiology Screening Tool (PEST) to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corrona Psoriasis Registry. ( 30663130 )
2019
36
Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. ( 30674475 )
2019
37
The impact of having family history of psoriasis or psoriatic arthritis on psoriatic disease. ( 30680951 )
2019
38
Association Between Psoriasis with Arthritis and Hearing Impairment in US Adults: Data from the National Health and Nutrition Examination Survey. ( 30647186 )
2019
39
Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis. ( 30552173 )
2019
40
Case of psoriasis vulgaris with atrial fibrillation, heart failure and chronic kidney disease which were found accidentally through blood examination during apremilast treatment. ( 30663127 )
2019
41
Exacerbation of Psoriasis with Pustulation by Sorafenib in a Patient with Metastatic Hepatocellular Carcinoma. ( 30745643 )
2019
42
Secukinumab decreased circulating anti-BP180-NC16a autoantibodies in a patient with coexisting psoriasis vulgaris and bullous pemphigoid. ( 30628103 )
2019
43
Treatment with apremilast was beneficial for chronic graft-versus-host disease skin lesion in a patient with psoriasis. ( 30632183 )
2019
44
A Case Report of Successful Treatment of Crohn's Disease and Psoriasis With Guselkumab. ( 30863855 )
2019
45
Association Between Psoriasis and Dementia: A Population-Based Case-Control Study. ( 30649680 )
2019
46
Correlation between Serum Brain-Derived Neurotrophic Factor Level and Depression Severity in Psoriasis Vulgaris Patients. ( 30894916 )
2019
47
Epidemiology of Depression in Patients with Psoriasis: A Nationwide Population-based Cross-sectional Study. ( 30734048 )
2019
48
Screening for Depression and Suicidality in Psoriasis Patients: A Survey of U.S. Dermatologists. ( 30682396 )
2019
49
Depression Symptoms Predict Worse Clinical Response to Etanercept Treatment in Psoriasis Patients. ( 30408786 )
2019
50
A Comparison of Two Chronic Skin Conditions: Atopic Dermatitis and Psoriasis. ( 30859539 )
2019

Variations for Pustulosis of Palm and Sole

Expression for Pustulosis of Palm and Sole

Search GEO for disease gene expression data for Pustulosis of Palm and Sole.

Pathways for Pustulosis of Palm and Sole

GO Terms for Pustulosis of Palm and Sole

Biological processes related to Pustulosis of Palm and Sole according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.65 IL36RN TNF TNFRSF1B
2 positive regulation of JNK cascade GO:0046330 9.51 IL36RN TNF
3 cytokine-mediated signaling pathway GO:0019221 9.5 IL36RN TNF TNFRSF1B
4 tumor necrosis factor-mediated signaling pathway GO:0033209 9.49 TNF TNFRSF1B
5 positive regulation of interleukin-6 production GO:0032755 9.46 IL36RN TNF
6 humoral immune response GO:0006959 9.43 CCR6 TNF
7 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.4 TNF TNFRSF1B
8 extrinsic apoptotic signaling pathway GO:0097191 9.37 TNF TNFRSF1B
9 cellular response to lipopolysaccharide GO:0071222 9.33 IL36RN TNF TNFRSF1B
10 negative regulation of interleukin-6 production GO:0032715 9.26 IL36RN TNF
11 positive regulation of membrane protein ectodomain proteolysis GO:0051044 8.96 TNF TNFRSF1B
12 immune response GO:0006955 8.92 CCR6 IL36RN TNF TNFRSF1B

Sources for Pustulosis of Palm and Sole

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....